A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-11

Study Completion Date

2025-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn how the medicine called itraconazole and food changes how the body processes another study medicine called PF-07258669 in older adults or healthy adults.

The study medicine PF-07258669 is developed for the treatment of unintended weight loss in older adults. People with this condition have decreased appetite and food intake, which is an important reason for poor nutrition and health results in people with unintended weight loss. The study has two parts: Part A and Part B.

The study is seeking participants who:

1. Are males or females who can no longer have children.
2. Part A Only: Are at least 65 years old and in reasonably good health. Part B Only: Are at least 18 years old and in good health.
3. Part A Only: Have a body mass index (BMI) of 16 to 27 kilogram per meter squared and a total body weight of more than 40 kilograms (88 pounds). Part B Only: Have a BMI of 16-32 kilogram per meter squared and a total body weight of more than 50 kilograms (110 pounds).

For Part A: Participants will take the study medicine PF-07258669 as tablets by mouth once on Day 1 at the study clinic and stay at the clinic for about 12 days. Then starting on Day 4, participants will take itraconazole as liquid by mouth for eight days. On Day 7, itraconazole will be taken together with PF-07258669.

For Part B: Participants will take the study medicine PF-07258669 as tablets by mouth once on Day 1 without breakfast at the study clinic and stay at the clinic for about 7 days. On Day 4, participant will take the study medicine after breakfast. A different group of participants will follow a similar procedure, but they will take the medicine after breakfast on Day 1 and without breakfast on Day 4.

For Parts A and B: At the clinic, the study team will observe the participants and take urine and blood samples to look at the levels of PF-07258669. The participants will receive a follow up telephone call about one month later.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

NCT07086664

Healthy Volunteers

ACTIVE_NOT_RECRUITING PHASE1

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

NCT01749085

Healthy Volunteers

COMPLETED PHASE1

AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

NCT02163161

Healthy

COMPLETED PHASE1

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

NCT05129475

Healthy Participants

COMPLETED PHASE1

Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects

NCT02058784

Healthy Volunteers Moderate to Heavy Smokers Non-smokers

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Parts A and B are not masked. Part A is not randomized. Part B is randomized to Sequence 1 or Sequence 2.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: Period 1

A single oral dose of PF-07258669 on Study Day 1

Group Type EXPERIMENTAL

PF-07258669

Intervention Type DRUG

Tablet

Part A: Period 2

Itraconazole QD orally on Study Days 4 to 11. PF-07258669 will be co administered on Study Day 7.

Group Type EXPERIMENTAL

PF-07258669

Intervention Type DRUG

Tablet

Itraconazole

Intervention Type DRUG

Solution

Part B: Sequence 1

A single oral dose of PF-07258669 on Study Days 1 and 4 under fasted and fed conditions respectively.

Group Type EXPERIMENTAL

PF-07258669

Intervention Type DRUG

Tablet

Part B: Sequence 2

A single oral dose of PF-07258669 on Study Days 1 and 4 under fed and fasted conditions respectively.

Group Type EXPERIMENTAL

PF-07258669

Intervention Type DRUG

Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-07258669

Tablet

Intervention Type DRUG

Itraconazole

Solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females who can no longer have children.
2. Part A Only: At least 65 years old. Part B Only: At least 18 years old.
3. In reasonably good health.
4. Part A Only: Body mass index (BMI) of 16-27 kg/m2; and a total body weight \>40 kg (88 lb.). Part B Only: BMI of 16-32 kg/m2; and a total body weight \>50 kg (110 lb.).

Exclusion Criteria

1. Evidence or history of clinically significant medical conditions.
2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb).
3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
4. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes